gsk201604296k7.htm
FORM 6-K
 
 
SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549
 
 
Report of Foreign Issuer
 
 
Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934
 
 
 
For period ending 29 April 2016
 
GlaxoSmithKline plc
(Name of registrant)


 
 
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)


 
 
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F


 
 
Form 20-F x     Form 40-F

 
--

 
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.


 
 
Yes      No x
--

 
GlaxoSmithKline plc
 
 Notification of Transactions of Directors, Persons Discharging
Managerial Responsibilities or Connected Persons
 
The Administrators of the GlaxoSmithKline 2009 Performance Share Plan (the 'Plan') notified GlaxoSmithKline plc ('GSK') on 28 April 2016 that the under-mentioned Directors, Persons Discharging Managerial Responsibilities ('PDMR') and Connected Persons acquired notional Ordinary Shares at a price of 1502.00 pence per Ordinary Share and American Depositary Shares ('ADSs') at a price of $42.64 per ADS, following the notional re-investment of the dividend paid to shareholders on 14 April 2016.
 
 
Director/PDMR
Ordinary Shares
ADSs
Sir Andrew Witty
41,688.082
 
Dr M M Slaoui
 
12,095.870
Mr S Dingemans
17,503.320
 
Mr R G Connor
8,568.501
 
Mr N Hirons
2,666.231
215.628
Mr S A Hussain
17,903.405
 
Mr D S Redfern
6,379.260
 
Ms C Thomas
8,495.290
 
Mr P C Thomson
4,638.016
 
Mr D E Troy
 
7,534.332
Dr P J T Vallance
18,629.480
 
Ms E Walmsley
14,203.165
 
Mrs V A Whyte
1,072.219
 
 
 
 
 
Connected Person
 
Ordinary Shares
 
       ADSs
Dr K Slaoui (Connected Person to Dr M M Slaoui)
 
184.627
 
The notional dividends accrued will be paid out in proportion to the percentage of participants' Plan holdings that vest following the end of the relevant measurement period.
 
 
This notification relates to transactions notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a) and (c).
 
V A Whyte
Company Secretary
 
29 April 2016
 

 
 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.



 
 
GlaxoSmithKline plc
(Registrant)


Date: April 29, 2016 
 
 
By: VICTORIA WHYTE
----------------------
 
 
Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc